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Preventing relapse in bipolar disorder
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Bipolar disorder is a life long condition characterized by
an irregular pattern of acute episodes separated by periods
of full or partial remission. While keeping patients well
after a remission is a primary therapeutic goal, relapse
rates have remained high despite the wide spread use of
lithium. There are now well powered double blind pla-
cebo controlled studies demonstrating the efficacy of lith-
ium [1], valproate [2], lamotrigine [3], olanzapine [4-6],
and aripiprazole for one or more outcome measure
related to prophylaxis.
Understanding the design of these clinical trials can help
interpretation of the results for clinical practice. Tradition-
ally the maintenance phase of treatment for patients with
mood disorder was conceptualized as therapeutic target
separate from the acute and continuation phase. Most
randomized clinical trials demonstrating prophylactic
treatment benefit, however, use an "enriched design".
Rather than randomizing already recovered patients to
start study medications, enriched designs begin with sub-
jects who have met criteria for acute response while
already exposed to the study drug.
The success of the enriched study design supports contin-
uation of successful acute treatment and/or the integra-
tion of potential maintenance phase treatments into the
acute phase management plan.
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